Clinical Trials on Alzheimer's Disease

www.ctad-alzheimer.com

Preliminary Program

Boston, November 1-4, 2017

LATE CALL FOR ABSTRACTS
September 1-15, 2017

www.ctad-alzheimer.com
Welcome ................................................................. p. 3
Program ................................................................. p. 4
  - Wednesday, November 1  ......................... p. 4
  - Thursday, November 2  ......................... p. 5
  - Friday, November 3  ......................... p. 7
  - Saturday, November 4  ......................... p. 9
Registration/Accommodations .......... p. 11
Dear Colleague,

The development of the next generation of Alzheimer’s disease treatments is among the most important health needs worldwide, but presents huge challenges. The goal of the meeting is to bring together today’s worldwide leaders in the treatment of Alzheimer’s disease to discuss new results, candidate therapeutics, and methodological issues important to the development of the next generation of Alzheimer’s disease treatments.

Clinical trial teams from worldwide centers will report on their efforts to identify new biomarkers of disease as well as more sensitive clinical assessment tools to identify those at risk for AD, to predict progression, and assess the effectiveness of new treatments.

At CTAD 2017 several teams will report the results of their preclinical, Phase II and Phase III trials. This sharing of experiences converges towards a same goal: overcoming the hurdles and speed the development of effective treatments in AD.

We look forward to welcoming you to Boston this November!

Jacques Touchon MD, PhD
University
Hospital of Montpellier
France

Bruno Vellas MD, PhD
University
Hospital of Toulouse
France

Paul Aisen MD
Alzheimer’s
Therapeutic Research Institute (ATRI)
University of Southern California (USC),
San Diego, USA

Mike Weiner MD
University of California
San Francisco (UCSF)
USA
Welcome from the Organizing Committee and CTAD Award for Lifetime Achievement in Alzheimer’s Disease Research

Keynote 1
The Evolution of Preclinical Alzheimer’s disease: Implications for Prevention Trials
Reisa Sperling, MD
Professor of Neurology, Harvard Medical School
Director, Center for Alzheimer Research and Treatment
Brigham and Women’s Hospital and Massachusetts General Hospital Memory Disorders Unit Boston, USA

Symposium 1
Importance of Serotonin in Alzheimer’s Disease Psychosis and the Potential Role of Pimavanserin
Moderator: Jeffrey Cummings, MD, ScD, Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA

1. Role of 5-HT2a Receptors in the Pharmacology of Alzheimer’s disease Psychosis
Stephen M. Stahl, MD, PhD1, Ethan S. Burstein, PhD2
(1) University of California, San Diego, CA, USA ; (2) ACADIA Pharmaceuticals Inc., San Diego, CA, USA

2. Clinical Trial of Pimavanserin in Alzheimer’s disease Psychosis
Clive Ballard, MBChB, MRCPsych1, Carol Banister, MBChB, MRCPsych2, Jim Youakim, MD3, Bruce Coate, MPH4, Srdjan Stankovic, MD, MSPH5, on behalf of the ADP Investigators
(1) University of Exeter Medical School, Exeter, UK ; (2) King’s College, London, UK ; (3) ACADIA Pharmaceuticals Inc., San Diego, CA, USA

3. Review of Pimavanserin Clinical Results in the Context of Historical Alzheimer’s disease Psychosis Trials
Pierre N. Tariot, MD1, Randall Owen, MD2, Doral Fredericks, PharmD, MBA2
(1) Banner Alzheimer’s Institute and University of Arizona College of Medicine, Phoenix, AZ, USA ; (2) ACADIA Pharmaceuticals Inc., San Diego, CA, USA
OC1 - A Phase 2a Exploratory Endpoint Trial in Mild-Moderate Alzheimer’s Disease of LM11A-31-BHS p75 neurotrophin receptor ligand.

Franth N. Longo, MD, PhD; Manfred Windisch, PhD; Niels Andreassen, MD; Agneta Nordberg, MD, PhD

(1) Department of Neurology, Massachusetts General Hospital, Boston, MA, USA; (2) NeuroScics GmbH, Graz, Austria; (3) Department of Neurobiology, Karolinska Institute, Stockholm, Sweden; (4) Center for Alzheimer’s Research, Karolinska Institute, Stockholm, Sweden

OC2 - Tau Accumulation Observed using Repeated Tau PET Measures Predicts Cognitive Decline in Normal Elderly

Bernard Hansewuy1,2, Beth Morrow1, Alex Becher1, Aaron Schulz1, Jorge Sepulcre1, Kathryn Papp3,4, Heidi Jacobs1, Jasmeet Chhatwal5, Dorene Rentz5,6, Reisa Sperling7,8, and Keith Johnson7,8

(1) Department of Radiology, Massachusetts General Hospital, Boston, MA, USA; (2) Department of Neurology, Cliniques Universitaires Saint-Luc, Brussels, Belgium; (3) Department of Neurology, Massachusetts General Hospital, Boston, MA, USA; (4) Center for Alzheimer Research and Treatment, Department of Neurology and Neurological Sciences, Stanford University, Palo Alto, CA, USA

OC3 - Clinical evaluation of #F-PI-2620, a next generation TAU PET agent in subject with Alzheimer disease and progressive supranuclear PALSy

Andrew Stephens1, John Seiby1, Andre Mueller1, Olivier Barret1, Mathias Berndt1, Jennifer Madonia2, David Alagille2, Hanno Schieferstein1, Heiko Kroth1, Santiago Bullich1, Andrea Pfeifer1 Andreas Muhs1, Gilles Tamagnan1, Kenneth Marell1, Ludger Dinzelbacher1

(1) Piramal Imaging, Berlin, Germany; (2) Molecular Neuroimaging, New Haven, USA; (3) AC Immune SA, Lausanne, Switzerland

OC4 - Optimizing the Preclinical Alzheimer’s Cognitive Composite (PACC) with Semantic Scoring

Jeffrey Cummings MD

Puzzle

OC5 - Can IT Help with the Screening for Alzheimer’s Disease Trials? From EHR to Web-Based Cognitive Tests and e-Consent.

Michael W. Weiner, MD; Peter Schueler, MD13; J. Wesson Ashford, MD, PhD14,16; Bruno Vellas, MD, PhD18

(1) UCSF, San Francisco, USA; (2) ICON, Langen, Germany; (3) University Duisburg-Essen, Germany; (4) Stanford/VA Alzheimer’s Disease and Aging Clinical Research Centers, CA, USA; (5) VA Palo Alto Health Care System, CA, USA; (6) Stanford University, CA, USA

OC6 - Amyloid Beta Oligomers in Alzheimer’s Disease: a Missing Piece of the Alzheimer’s Puzzle

Jeffrey Cummings MD, PhD; Sandrine Andrieu MD, MPH; Philip Scheltens MD, PHD; Kaj Blennow MD, PHD; Petr Kocis PhD; John A. Hey PHD; A. Power, MD; Martin Tolar, MD, PHD; Susan Abushakra, MD

(1) Cleveland Clinic, Lou Ruvo Center for Brain Health, Las Vegas, Nevada; (2) University of Toulouse, Toulouse, France; (3) VU University Medical Center, Amsterdam, Netherlands; (4) The Sahlgrenska Academy at University of Gothenburg, Mölndal, Sweden; (5) Alzheimer’s Inc., Boston, MA, USA

Coffee Break and Poster Session

OC7 - ABBV-BE12, a Humanized Anti-Tau Monoclonal Antibody for the Treatment of Early Alzheimer’s Disease: A 96-Week, Multiple Dose, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study

Kumar Budur1, Hana Florian1, Deli Wang1, Weinig Robison1, Holly Soares1, Joel B. Braunsenn1, David M. Holtzman2, Randall J. Bateman1, Beatrice Rendebach-Muell1, Nuno Mendonca1

(1) AbbVie Inc, North Chicago, IL, USA; (2) C2N Diagnostics LLC, Saint Louis, MO, USA; (3) Washington University, St. Louis, MO, USA; (4) AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany

OC8 - Stratification of Pre-Symptomatic and Cognitively Normal Individuals using Polygenic Scoring

Maryam Shoai, PhD; Richard Pither, PhD; Valentina Escott-Price, PhD; Simon M Laws, PhD; Harold Hampel, MD, PhD; Simone Lista, PhD; Rik Vandenberghe1; Isabelle Cleyner1; David Irwin, MD, PhD; Vivian Van Deerlin, MD, PhD; Greg Davidson, PhD1; Virginia M.-Y. Lee, PhD; John Q. Trojanowski, MD, PhD; Duy Van; John Hardy, PhD, DSc

(1) UCL Institute of Neurology, London, United Kingdom; (2) Cypix Ltd, UK, Oxford, United Kingdom; (3) Cardiff University, Cardiff, United Kingdom; (4) Edith Cowan University, and Cooperative Research Centre (CRC) for Mental Health, Perth, Australia; (5) AAA Research Fund B-UPMC Chair, Paris, France; (6) Katholieke Universiteit Leuven, Leuven, Belgium; (7) Hospital of the University of Pennsylvania Department of Neurology, University of Pennsylvania, Philadelphia; (8) Hospital of the University of Pennsylvania, Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia; (9) Leducq Associates, UK; (10) Centre for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine, Philadelphia
OC9 - Objective Cognitive Decline in Preceding Years Relates to Self-Report on the Cognitive Function Index in the Harvard Aging Brain Study

Rebecca E. Amariglio PhD1,2, Rachel F. Buchley PhD2,3,4,5, Elizabeth C. Mormino PhD2,3, Dylan R. Kim MPH2, Gad A. Marshall MD2,3, Keith A. Johnson MD1,2,3, Dorene M. Rentz PsyD1,2, Reisa A. Sperling MD2,3

(1) Department of Neurology, Brigham and Women’s Hospital, Boston, MA, USA; (2) Department of Neurology, Massachusetts General Hospital, Boston, MA, USA; (3) Harvard Medical School, Boston, MA USA; (4) Florey Institutes of Neuroscience and Mental Health, Melbourne, Australia; (5) Melbourne School of Psychological Science, University of Melbourne, Australia

OC10 - The Generation Program : Evaluating CNP520 Efficacy in Preclinical Alzheimer’s Disease

Cristina Lopez Lopez, MD, PhD1, Pierre N. Tariot, MD2, Angelita Caputo, PhD3, Fonda Liu, Pharm.D4, Marie-Emmanuelle Riviere, PhD5, Marie-Laure Rouzade-Dominguez, PhD6, Ronald G. Thomas, PhD7, Jessica B. Langbaum, PhD8, Rob Lenz, MD, PhD9, Eric M. Reiman, MD, PhD10, Ana Graf, MD11

(1) Novartis Pharma, Basel, Switzerland; (2) Banner Alzheimer’s Institute, Phoenix, AZ, USA; (3) University of California-San Diego, San Diego, CA, USA; (4) Amgen, Thousand Oaks, CA, USA.

Symposium 2
CTAD 2017 Statistical Workshop : Estimands and Primary Analyses in AD Clinical Trials

Moderator : Hong Liu-Seifert Ph.D.
Eli Lilly and Company, Indianapolis, IN USA
Fabian Model Ph.D.
Roche, Basel, Switzerland
Paul Aisen M.D.
Alzheimer’s Therapeutic Research Institute, University of Southern California, San Diego, CA, USA

Lunch and Poster Session

Late Breaking Oral Communications

Keynote 2
From Academy to Industry: Perspectives for Drug Trials in AD

Rachelle Doody, MD, PhD
Global Head of Neurodegeneration PD Neuroscience, F. Hoffmann-La Roche, Basel, Switzerland

Late Breaking Oral Communications

Coffee Break and Poster Session

Symposium 3
EPOCH Trial of the BACE1 Inhibitor Verubecestat for Mild-to-Moderate Alzheimer’s Disease

Michael Egan, MD1, James Kost, PhD2, Pierre N. Tariot, MD3, Paul S. Aisen, MD3, Jeffrey L. Cummings, MD, ScD4, Bruno Vellas, MD Ph.D5, Yuni Mulrai, MD6, Tiffini Voss, MD7, Christine Furrer, MS3, Erin Mahoney, MS8, Rith Vandenberghe, MD, PhD9, Yi Mo, PhD10, David Michelson, MD11

(1) Merck & Co., Inc., Kenilworth, NJ, USA; (2) Banner Alzheimer’s Institute, Phoenix, AZ, USA; (3) University of Southern California, San Diego, CA, USA; (4) Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA; (5) Gerontopole, INSERM U 1027, Alzheimer’s Disease Research and Clinical Center, Toulouse University Hospital, Toulouse, France; (6) University Hospital of Leuven, Leuven, Belgium
OC11 - Long-Term Cognitive Decline in Patients with Alzheimer’s Disease in Association with Treatment with Cholinesterase inhibitors-data from SveDem, the Swedish Dementia Registry

Marja Erflotsdotter MD, PhD1,2, Sara Garcia-Prace8 MD, PhD1,2, Ingemar Kåreholt PhD3, Dorota Religa MD, PhD1,2, Peter Nordström MD, PhD4, Anders Wimo MD, PhD1,2, Bengt Winblad MD, PhD1,2

(1) Department of Neurology, Care Sciences and Society, Center for Alzheimer Research, Division of Clinical Genetics, Karolinska Institutet, Huddinge, Sweden ; (2) Department of Genomic Medicine, Karolinska University Hospital, Huddinge, Sweden ; (3) Aging Research Center, Center for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholms Universitet, Stockholm, Sweden ; (4) Institute of Gerontology, School of Health and Welfare, Jönköping University, Jönköping, Sweden ; (5) Department of Neurobiology, Care Sciences and Society, Center for Alzheimer Research, Division for Neurogenetics, Karolinska Institutet, Huddinge, Sweden ; (6) Department of Community Medicine and Rehabilitation, Genomic Medicine, Umeå University, Umeå, Sweden ; (7) The primary health care of Hudiksvall-Nordenswärd, Sweden

OC12 - Selection of Amyloid Positive Pre-Symptomatic Subjects using Automatic Analysis of Neuropsychological and MRI Data for Cost-Effective inclusion Procedures in Clinical Trials

Marion Anwar, MSc1, Stéphane Epelbaum, MD, PhD2,3, Olivier Colliot, PhD2,3, Didier Dormont, MD2,3, Bruno Dubois, Prof, MD2,3, Harald Hampel, Prof, MD, PhD2,3, Stanley Durrieulement, PhD2, for the ADNI, and the INSIGHT study group

(1) Sorbonne Universités, UPMC Univ Paris 06, Inserm, CNRS, Institut du cerveau et de la moelle (ICM) - Hôpital de la Pitié-Salpêtrière, Boullevard de l’hôpital, Paris, France ; (2) Inria Paris, Aramis project-team, Paris, France ; (3) AP-HP, Hôpital de la Pitié-Salpêtrière, Department of Neurology, Institut de la Mémoire et de la Maladie d’Alzheimer (IM2A), Paris, France ; (4) API-HP, Hôpital de la Pitié-Salpêtrière, Department of Neuroradiology, Paris, France ; (5) AXA Research Fund & UPMC Chair, Paris, France

OC13 - Physical Activity and Longitudinal Cognition: Results from the Harvard Aging Brain Study

Hannah M. Klein1, Dylan R. Kirm, MPH1, Aaron P. Schultz, PhD3, Jennifer S. Rabin, PhD3, Rachel Buckley, PhD3,4, Dorene M. Rentz, PsyD1,2, Kathryn V. Papp, PhD2,3, Keith A. Johnson, MD2,3, Reisa A. Sperling, MD MMSc3,4, Jasmine P. Chhatwal, MD,PhD MMSc1,2, Ryan Walter, BS1,2, Yuka Maruyama, D.V.M.3, Ann M. Saunders, PhD4

(1) Department of Neurology, Massachusetts General Hospital, Boston, MA, USA ; (2) Department of Neurology, Brigham and Women’s Hospital, Boston, MA, USA ; (3) Harvard Medical School, Boston, MA USA ; (4) Institute of Gerontology, School of Health and Welfare, Jönköping University, Jönköping, Sweden ; (5) Flinn Institutes of Neurosciences and Mental Health, Melbourne, Australia ; (6) Flinn School of Psychological Sciences, University of Melbourne, Melbourne, Australia

OC14 - Validation of Tau PET Imaging in Alzheimer’s Disease and Other Tauopathies

Niklas Mattsson, MD, PhD,2, Michael Schöll MD, PhD,1, Tomas Ohlsson MD, PhD,1, Andreas Hahn MD, PhD,1,2, Olaf Strandberg MD, PhD,1,2, Phas Jiogi MD, PhD1,2, Ruben Smith MD, PhD1,2,3

(1) Clinical Memory Research Unit, Department of Clinical Sciences, Malmö, Lund University, Sweden ; (2) Memory Clinic, Skåne University Hospital, Malmö, Sweden ; (3) Department of Radiation Physics, Skåne University Hospital, Lund, Sweden ; (4) Department of Psychiatry and Neurology, Institut de la Mémoire et de la Maladie d’Alzheimer (IM2A), Paris, France ; (5) Department of Clinical Physiology and Nuclear Medicine, Skåne University Hospital, Lund, Sweden ; (6) Department of Neurology, Slöde University Hospital, Lund, Sweden

OC15 - TOMMORROW: A Trial to Delay the Onset of MCI Due to AD and Qualify a Unique Genetic Algorithm Biomarker: Study Update

Kathleen A. Welsh-Bohmer, PhD1, Brenda L. Plassman, PhD1, Carl Chiang, PhD1, Meredith Culp, BS1, Patrick Harrigan, BCH1, Janet O’Neil, MBA1, Ryan Walter, BS5, Stephen Haneline, MS1, Julian Arbuckle, BSc (Hons)1, Shayama Brewster, BSc (Hons)1, Yuka Maruyama, D.V.M.1, Tom Swanson, BSCE, MBA1, Dominic Fitzsimmons, BSc (Hons)1, Alexandra S. Atchins, PhD1, Sarah Knowell, MSc1, Richard Keefe, PhD2, Craig Metz, PhD1, Daniel K. Burns, PhD1, Ann M. Saunders, PhD1, Ferenc Martenyi, MD1 for the TOMMORROW study investigators

(1) Department of Psychiatry & Neurology, Duke University, Durham NC, USA ; (2) Zinfandel Pharmaceuticals, Inc., Chapel Hill NC, USA ; (3) Takeda Development Center Americas, Inc., Deerfield, IL, USA ; (4) NeuroCog Trials, Durham, NC, USA

OC16 - Emerging Plasma-Based Therapies for AD

Montse Costa PhD1, D. Allan Butterfield PhD2, Norman Reltin MD, PhD3

(1) Griffins Institute S.A., Parets del Vallès, Spain ; (2) Department of Chemistry, University of Kentucky, Lexington KY, USA ; (3) Reltin Consulting LLC, New Jersey, USA

Coffee Break and Poster Session

10:00 – 10:30 a.m.

Keynote 3

Genetic Aspects In Clinical Trials

John Hardy, Reta Lila Weston Institute of Neurological Studies, University College London, London, UK

10:30 – 11:00 a.m.

OC17 - Cognitive Run-In Periods for Amyloid-Positive Enriched Secondary Prevention Trials.

Andrew J. Aschenbrenner1, PhD, Jason Hassenstab2, PhD, Eric McDade1, DO, Guoqiao Wang2, PhD, Tammie L.S. Benzinger1, MD, PhD, Randall J. Bateman, MD, & John C. Morris1, MD

(1) Department of Neurology, Washington University in St. Louis ; (2) Department of Psychological and Brain Sciences, Washington University in St. Louis ; (3) Department of Biostatistics, Washington University in St. Louis ; (4) Department of Radiology, Washington University in St. Louis

11:00 – 12:30 p.m.

Oral Communications

CTAD 2017
Friday, November 3

OC18 - Eigen Combinations of Cognition and Biomarkers to Minimize the Sample Sizes in Prevention Trials on Alzheimer Disease

Chengjie Xiong1,2,3,4, PhD, Anne M. Fagan2,3,4, PhD, Tammie Benzinger7,5, PhD, Jason Hassenstab8,3,5, PhD, John C. Morris2,3, MD, Randall J. Bateman2,3,5, MD.

(1) Division of Biostatistics, Washington University School of Medicine, St. Louis, MO, USA; (2) Knight Alzheimer Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA; (3) Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA; (4) Department of Mathematics, Washington University School of Medicine, St. Louis, MO, USA; (5) Department of Radiology, Washington University School of Medicine, St. Louis, MO, USA; (6) The Dominantly Inherited Alzheimer Network, Washington University School of Medicine, St. Louis, MO, USA

OC19 - The Alzheimer’s Prevention Registry and GeneMatch: Accelerating Recruitment and Enrollment into Alzheimer’s Studies

Jessica B. Langbaum, PhD1, Nellie High2, David Gordon1, Jodie Nichols1, Trisha Walsh1, Eric M. Reiman1, MD, Pierre N. Tariot2, MD

(1) Banner Alzheimer’s Institute, Phoenix, AZ, USA

OC20 - An Examination of Rate of Decline as an Alternative to Change from Baseline

Howard Macheys, PhD1, Nan Hu, PhD2, Michael Ahmadi, MSc2, Yinghua Chen, MSc1, Pierre Tariot, MD1, Eric M Reiman1, MD, Francisco Lopera, MD1, Kewei Chen, PhD2, Ronald Thomas, PhD1

(1) Genentech, Inc., South San Francisco, CA, USA; (2) Banner Alzheimer’s Institute, Phoenix, AZ, USA; (3) Universidad de Antioquia, Medellin, Colombia; (4) UC San Diego Department of Neurosciences, CA, USA

OC21 - The Safety and Efficacy of Edoneric (T-817) in Patients with Mild to moderate Alzheimer’s Disease

Lon S. Schneider, MD1, Ronald G. Thomas, PhD2, James Brewer, MD3, Suzanne Hendrix, PhD3, Robert Rissman, PhD2, David Salmon, PhD1, Hiroshi Kobayashi, MD2, Howard Feldman, MD1, for the ADCS TCAD group

(1) Keck School of Medicine of the University of Southern California, Los Angeles, CA, USA; (2) University of California, San Diego, CA, USA; (3) Pentara Corporation, San Diego, CA, USA; (4) Tokyo Chemical, Ltd, Tokyo, Japan

OC22 - Safety of and Tolerability of Gantenerumab in the Open-Label Extension of SCarlet RoAD Trial, a Global Study in Patients with Prodromal Disease

Miriana Ardeltilhovic, PhD1, Danielle Abi-Saab1, PsyD1, Nathalie Pross1, PhD1, Paul Delmar, PhD2, Nicola Voyle, PhD2, Michaela Mertes3, Smiljana Ristic, MD1

(1) Hoffman LaRoche, Basel, Switzerland; (2) Roche Products Limited, Welwyn, UK

Coffee Break and Poster Session

Keynote 4

Rationale, Design and Progress of the 3 Active Alzheimer’s Prevention Initiative Trials

Pierre Tariot, MD, Banner Alzheimer’s Institute, University of Arizona College of Medicine, Phoenix, AZ - USA

Symposium 4

Results from the Phase 3 MINDSET STUDY: A Global, Double-Blind, Placebo-Controlled Study of Intepridine in Mild-to-Moderate Alzheimer’s Disease

• Presentation 1: Analysis of primary efficacy and safety results
• Presentation 2: Analysis of secondary endpoints and measures of clinical meaningfulness
• Discussion and Q&A
**Saturday, November 4**

**08:30 – 10:00 a.m. Oral Communications**

**OC25 - ORY-2001 Rationale in Mild to moderate Alzheimer’s Disease**
Roger Bullich MD, Cesar Molinero MD,PhD, Tamara Maes PhD
(1) Oryzon Genomics S.A. Barcelona Spain

**OC26 - Plasma Amyloid Levels within the Alzheimer’s Process and Correlations with Central Biomarkers**
Olivier Hanon, MD, PhD1, Jean-Sébastien Vidal MD, PhD2, Sylvain Lehmann MD, PhD2, Stéphanie Bombois MD, PhD2, Bernadette Allinguant MD2, Marie Godard Msc, Patrick Gelé MD1, Christine Delmaire MD1, Frédéric Blanc MD3, PhD2, S Schraen MD, Audrey Gabelle MD, PhD1 and the BALTAZAR study group.
(1) Department of Gerontology, Bruco Hospital, Paris, France ; (2) Laboratoire de Phrotomique Cline, Department of Biochemistry, Saint Eloi Hospital, INSERM, Inserm U1083, France ; (3) CMRR de Lille, Department of Neurology, Lille, France ; (4) Centre de Psychiatrie et Neurosciences, Université Paris Descartes, Paris, France ; (5) University of Lille Nord de France, Department of Biology and Pathology, Lille University Hospital, INSERM UMR 1725, 59037 Lille, France ; (6) CMRR de Strasbourg, Department of Gerontology, Strasbourg, France ; (7) CMRR de Montpellier, Department of Neurology, Inserm U1083, Montpellier, France.

**OC27 - Online Clinical Research: Updates and Insights from the Brain Health Registry**
Shannon Finley, MA1, Diana Truran1, Dereth Fennleni2,3, Juliet Fochet1,2, Rachel L Nosheny PhD1,2, Monica Camacho1,2, R Scott Machin PhD1,2 and Michael W Weiner MDb,c
(1) Center for Imaging of Neurodegenerative Diseases, San Francisco Veteran's Administration Medical Center, San Francisco, CA, USA ; (2) UCSF Department of Psychiatry, San Francisco, CA, USA ; (3) UCSF Department of Radiology and Biomedical Imaging, San Francisco, CA, USA.

**OC28 - BPN14770 Phosphodiesterase-4D Negative Allosteric Modulator for Alzheimer’s Dementia: Preclinical, PET Imaging and Human Phase I Results**
Mark Gurney, PhD1, Chong Zhang PhD2, Ying Xu PhD2, James O’Donnell PhD2, Masahiro Fujita MD, PhD2, Robert Innis MD, PhD1, Victor Piñeiro PhD1, Sanjay Telu PhD1 and Scott Reines, MD, PhD2
(1) Terra Discovery Partners, Inc. Grand Rapids, MI, USA ; (2) School of Pharmacy and Pharmacological Sciences, University at Buffalo, Buffalo, NY, USA ; (3) National Institute of Mental Health, Bethesda, MD, USA.

**OC29 - Amyloid Beta Stable Isotopic Labeling Kinetics and Concentrations of Human Plasma Detect CNS Amyloidosis**
Vitaliy Ovod MS1, Kara Ramsey, BS2, James Bollinger PhD3, Kwasi Mawuenyega, PhD, Terry Hichts, BA1, Theresa Schneider1, Thomas Kasten, PhD, Wendy Sigurdson, RN1, Melissa Sullivan, MS1, Tamara Donahue, RN, Katrina Paumier, PhD1, David Holtzman, MD1,2,4, John Morris, MD1,2,4, Tammy Benzinger MD, PhD1,3,4, Anne Fagan PhD1,2,4, Vitaly Ovod PhD1,2,4, Bruce Patterson, PhD1, and Randall Bateman, MD2,4,5
(1) Department of Neurology, Washington University School of Medicine, St Louis, MO, (2) Hope Center for Neurological Disorders, Washington University School of Medicine, St Louis, MO, (3) Department of Radiology, Washington University School of Medicine, St Louis, MO, (4) Knight Alzheimer’s Disease Research Center, Washington University School of Medicine, St Louis, MO, (5) Department of Medicine, Washington University School of Medicine, St Louis, MO.

**OC30 - Stereotypical Data-Driven Imaging Biomarker Trajectories across the Alzheimer’s Disease Spectrum**
Sergey Shcherbinin, PhD1, Mark A. Mintun, MD2, Adam J. Schwarz, PhD1, For the Alzheimer’s Disease Neuroimaging Initiative2
(1) Eli Lilly and Company, Indianapolis, IN, USA ; (2) Avid Radiopharmaceuticals, Inc., Philadephia, PA, USA ; Alzheimer’s Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu).

**Coffee Break and Poster Session**

**10:00 – 11:00 a.m. Late Breaking Oral Communications**

**Symposium 5**

**Synaptic and Network Dysfunction in Alzheimer’s Disease (AD): Translational Insights and Therapeutic Opportunities**
Moderator: Arjen Brussard, PhD, Amsterdam Neuroscience, VU Medical Center, Amsterdam, Netherlands

1. Targeting unfolded protein response and synaptic dysfunction to enhance memory function and prevent neurodegeneration
Giovanna Mallucci, MD PhD1,2
(1) Dept. of Clinical Neurosciences, University of Cambridge, Cambridge, UK ; (2) UK Dementia Research Institute at University of Cambridge, Cambridge, UK.

2. Modulation of synaptic and network activity and endocytosis with light ficher therapy reduces amyloid pathology in mouse model of AD
Li-Huei Tsai, PhD1
(1) Picower Institute of Memory and Learning, Massachusetts Institute of Technology, Cambridge, MA, USA.

3. Preclinical rationale and early clinical results of p38 alpha kinase inhibition to reverse hippocampal synaptic dysfunction
John Alam, MD1
(1) EIP Pharma, LLC, Cambridge, MA, USA.
Lunch and Poster Presentation

Late Breaking Oral Communications

Oral Communications

OC31 - A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Sequential Cohort, Dose-Ranging Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of TPI 287 (abeotaxane) in Patients with Primary Four Repeat Tauopathies: Corticobasal Syndrome or Progressive Supranuclear Palsy; or the Secondary Tauopathy, Alzheimer’s Disease.

Adam Boxer, MD, PhD; Zachary Miller, MD; Richard Tsai, MD, MBA; Mary Koestler, RN, PhD; Julio Rojas, MD, PhD; Peter Lubenkow, MD; Howie Rosen, MD; Gil Rabinovici, MD; Anne Fagan-Niven, PhD; Yann Cobigo, PhD; June Jung, PhD; Phi Luong, BS; Emmeline Chuu, BA; Ryan Powers, BA; Paige Mumford, BA; Bruce Miller, MD; Erik Roberson, MD, PhD

(i) Memory and Aging Center, Department of Neurology, University of California, San Francisco, CA, USA ; (2) Department of Neurology, Washington University School of Medicine, Saint Louis, MO, USA ; (3) Department of Neurology, University of Alabama School of Medicine, Birmingham, AL, USA


Jason Hassenstab, PhD; Andrew J. Aschenbrenner, PhD; Martin J. Sliwinski, PhD; Eric McDade, DO; Yen Ying Lim, PhD; Paul Maruff, PhD; David A. Balota, PhD; John C. Morris, MD; Randall J. Bateman, MD; The Dominantly Inherited Alzheimer Network-Trials Unit

(i) Department of Neurology, Washington University School of Medicine, St. Louis, MO USA ; (2) Department of Psychological & Brain Sciences, Washington University, St. Louis, MO, USA ; (3) The Dominantly Inherited Alzheimer Network-Trials Unit (DIAN-TU), Washington University School of Medicine, St. Louis, MO USA ; (4) Knight Alzheimer’s Disease Research Center, Washington University School of Medicine, St. Louis, MO USA ; (5) Department of Human Development and Family Studies, Pennsylvania State University, State College, PA USA ; (6) The Florey Institute, The University of Melbourne, Parkville, Victoria, Australia ; (7) Cogstate Ltd, Melbourne, Victoria, Australia

OC33 - Associating Cognitive Functioning Profiles with Amyloid Status in ADNI2, with Implications for Adaptive Screening for Amyloid

Sarah I Carr PhD; Judith Jaeger PhD; Nancy Maserejian ScD; Ahmed Enayatallah; Alan Lerner; Yanming Wang; Sheng Yang; Wenting Wang; Shijia Biang; Curtis Tatsuoka PhD; and for the Alzheimer’s Disease Neuroimaging Initiative*

(i) Department of Neurology, Case Western Reserve University, Cleveland, OH, USA ; (2) CognitionMetrix, DE, USA ; (3) Department of Psychology and Behavioral Sciences, Albert Einstein College of Medicine, Bronx, NY, USA ; (4) Biogen, Cambridge, MA, USA ; (5) Neurological Institute, University Hospitals, Case Medical Center, Beachwood, OH, USA ; (6) Department of Radiology, Case Western Reserve University, Cleveland, OH USA ; (7) Department of Epidemiology and Biostatistics, Case Western Reserve University, Cleveland, OH USA

OC34 - Alzheimer’s Disease Dementia and the Long-Term Impact on Caregiver Burden – 36-Month results from CERAS

Catherine Reed, PhD; Mark Belger, BSc; I. Scott Andrews, PharmD; Antje Tochhorn-Heidenreich, MSc.

(i) Eli Lily and Company Limited, Windlesham, UK ; (2) Eli Lilly and Company, Indianapolis, IN, USA

OC35 - Neuroprotective Effect of a New Photobiomodulation Technique against Amyloid Aβ25-35 Peptide-Induced Toxicity in Mice.

Guillaume J. Blivet, MSc; Johann Meunier, PhD; Francesco J. Roman, PhD; Jacques Touchon, MD, PhD

(i) REGEnLIFE SAS, Montpellier, France ; (2) Armixis SAS, Montpellier-sur-Léz, France ; (3) INSERM U1066, Montpellier, France

OC36 - Investigational New Alzheimer’s Drug Tricaprilin: Results of a Phase 3 Study in Mild-to-Moderate Alzheimer’s Disease Patients

Samuel Henderson, PhD; Michael Gold, MD; Judith Walker, MD; Sabrina Greer; Janet Vogel; Aaron Shenhin

(i) Accera Inc, Boulder, CO, USA ; (2) PPD Inc, Wilmington, NC, USA

OC37 - Characterization of the selective in vivo and in vitro binding properties of crenezumab: insights into crenezumab’s unique mechanism of action

William J. Melland; Janice A. Maloney; Jose Imperio; Travis W. Bainbridge; Milhe Reichelt; Danielle Mandikian; Yannel Lu; James A. Erns; Reina N. Fuji; Jasvinder K. Atwal

(i) Department of Neuroscience, Genentech, South San Francisco, CA, USA ; (2) Department of Protein Sciences, Genentech, South San Francisco, CA, USA ; (3) Department of Research Pathology, Genentech, South San Francisco, CA, USA ; (4) Department of Preclinical and Translational Pharmacology, Genentech, South San Francisco, CA, USA ; (5) Department of Biochemical and Cellular Pharmacology, Genentech, South San Francisco, CA, USA ; (6) Department of Safety Assessment, Genentech, South San Francisco, CA, USA

*OC31-OC37 will also be part of the Late-Breaking Oral Presentations session on Saturday, November 4.
**CTAD 2017**

## REGISTRATION

### Early bird fees (until September 1)

1. Regular Registration (no lunches) **895€** - Regular registration (with 3 lunches) **1024€**
2. EADC Member registration (no lunches) **704€** - Regular registration (with 3 lunches) **833€**
   (to benefit from this rate you must be an active member of the European Disease Consortium)

### Full registration fees (After September 2)

1. Regular Registration (no lunches) **1027€** - Regular registration (with 3 lunches) **1156€**
2. EADC Member registration (no lunches) **854€** - EADC Member registration (with 3 lunches) **983€**
   (to benefit from this rate you must be an active member of the European Disease Consortium)

Please note that registration to CTAD 2017 includes:
- access to all conference sessions, attendee bag, one-year online subscription to the Journal of Prevention of Alzheimer’s Disease (JPAD) and CTAD abstracts

You can register directly on our website www.ctad-alzheimer.com

## ACCOMMODATIONS

**Book your accommodation at the Conference Venue**

This year again CTAD has negotiated a special price to stay at the Boston Park Plaza where CTAD will be held.

**Boston Park Plaza**

50 Park Plaza at Arlington Street

Boston, MA 02116-3912

- The price for a single room is **279$** (including breakfast)
- The price for a double room is **319$** (including breakfast for 2 people)

Make sure your book your room early on to ensure you stay at the conference venue.

**Book your room on our website www.ctad-alzheimer.com**